2021 Translational Study: Galectin-3 in septic acute kidney injury: a translational study 2021 Preclinical Study: Galectin-3 participates in PASMC migration and proliferation by interacting with TGF-β1 2021 Translational Study: A translational study of Galectin-3 as an early biomarker and potential therapeutic target for ischemic-reperfusion induced acute kidney injury 2020 Preclinical Study: Galectin-3 Inhibition Reduces Diabetes-Associated Cognitive Impairment, Oxidative Stress and Neuroinflammation 2020 Review: Hyperinflammation and Fibrosis in Severe COVID-19 Patients: Galectin-3, a Target Molecule to Consider 2020 Review: A Potential Role for Galectin-3 Inhibitors in the Treatment of COVID-19 2020 Prospective Cohort Study: Gal-3 a Potential Biomarker of Vascular Calcification for Maintenance Hemodialysis (MHD) Patients 2020 Clinical Study: Galectin-3 a Biomarker for the Early Detection of Diabetic Kidney Disease (DKD) 2020 Review and Meta-analysis: Serum Galectin-3 is Associated with Increased Risk of Atrial Fibrillation Recurrence 2020 Preclinical Study: Gal-3 Signaling Pathway is Related to Pathogenesis of Atrial Fibrillation in Diabetes 2019 Preclinical Study: Galectin-3 Blocker Targets Galectin-3-Induced STAT3 Activation to Synergize with Chemotherapy Drug Paclitaxel Against Ovarian Cancer 2019 Preclinical Study: Galectin-3 Inhibition Improves Ischemic Heart Failure by Downregulating Galectin 3 and Reducing Myocardial Fibrosis 2019 Preclinical Study: Blockade of Galectin-3 Prevents Profibrotic and Proinflammatory Effects of Cardiotrophin-1 (CT-1) in Myocardial Fibrosis 2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Damage, Inflammation, and Fibrosis Following Kidney Injury 2019 Preclinical Study: Galectin-3 Inhibitor Reduces the Pro-Inflammatory, Pro-fibrotic, and Pro-osteogenic Response in Aortic valves in Patients Undergoing Aortic Valve Replacement 2019 Preclinical Study: Blockade of Galectin-3 Prevents Cardiac Fibrosis, Inflammation and Functional Alterations